We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
BioNTech's personalized mRNA therapy against NSCLC is on the way. The vaccine reduces the risk of melanoma recurrence by 49%. Learn about the future of personalized oncology.
